CHICAGO — At the Ophthalmology Innovation Summit here, Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics, discusses a new initiative by Spark to provide physicians and patients access to genetic testing for more than 30 genes linked to certain forms of inherited retinal diseases. The initiative is called the Identify Your Inherited Retinal Disease, or ID YOUR IRD.
Refractive prediction error is significantly less myopic in older patients, decreasing by approximately 0.06 D per decade, a new study showed. Medscape Medical News
Refractive prediction error is significantly less myopic in older patients, decreasing by approximately 0.06 D per decade, a new study showed. Medscape Medical News
Researchers from the Icahn School of Medicine at Mount Sinai have been awarded a $10 million from the National Cancer Institute to explore the cellular and molecular mechanisms of acute graft-versus-host disease (GVHD), a common side effect that occurs…
CHICAGO — The past year has seen a number of important approvals and promising study progress in both biotechnology and ophthalmic devices, Emmett T. Cunningham Jr., MD, PhD, MPH, told the more than 900 attendees at the Ophthalmology Innovation Summit in his “Chairman’s 2016 Year in Review.”Leading approvals this yearincludeShire’s Xiidra (lifitegrast), which isthe firstapproval of adry eyetreatmentin nearly 15 years, according to Cunningham.In addition, cross-linking from Avedro, which has been availableinternationallyfor some time,wasapproved for use in the United States.
CHICAGO — At the Ophthalmology Innovation Summit here, Barry J. Linder, MD, MS, chief medical officer for Clarity Medical Systems, discusses the launch of the Holos-Barrett IOL algorithm.